Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)

2016 ◽  
Vol 10 (3) ◽  
pp. 594-603 ◽  
Author(s):  
Calvin Yeang ◽  
Ming-Yow Hung ◽  
Young-Sup Byun ◽  
Paul Clopton ◽  
Xiaohong Yang ◽  
...  
Keyword(s):  
Therapeutic Interventions ◽  
Oxidized Phospholipids ◽  
Lipoprotein A ◽  
Apolipoprotein B100

Lp(a): der akzeptierte unabhängige Risikofaktor

2019 ◽  
Vol 23 (09) ◽  
pp. 388-391
Author(s):  
Volker Schettler
Keyword(s):  
Lipoprotein A ◽  
Apolipoprotein A ◽  
Apolipoprotein B100

Lipoprotein(a) (Lp(a)) besteht aus einem LDL-Partikel, an dem über das Apolipoprotein B100 des Partikels eine Disulfidbrücke zu einem Apolipoprotein(a) besteht ( Abb. 1 ). Obwohl Lp(a) bereits 1963 von Berg et al. erstmals als „lipoprotein associated antigen“ entdeckt 1 und schon früh ein Zusammenhang mit kardiovaskulären Ereignissen diskutiert wurde 2, konnten diese Annahmen der klinischen Eigenschaften erst deutlich später im Rahmen von epidemiologischen Evaluationen bestätigt werden 3, 4. Ab einer Lp(a)-Konzentration von über 30 mg/dl (> 75 nmol/l) besteht ein nahezu linearer Zusammenhang zwischen dem Anstieg der Lp(a)-Konzentration und kardiovaskulären Ereignissen wie Myokardinfarkt und das Risiko für eine Aortenklappenstenose 3, 4.

scholarly journals Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet

2010 ◽  
Vol 51 (11) ◽  
pp. 3324-3330 ◽  
Author(s):  
Nastaran Faghihnia ◽  
Sotirios Tsimikas ◽  
Elizabeth R. Miller ◽  
Joseph L. Witztum ◽  
Ronald M. Krauss
Keyword(s):  
High Carbohydrate Diet ◽  
Oxidized Phospholipids ◽  
Low Fat ◽  
Carbohydrate Diet ◽  
Lipoprotein A ◽  
High Carbohydrate

Lipoprotein(A), Oxidized Phospholipids, And Aortic Valve Microcalcification Assessed By 18f-Naf Pet/Ct

2019 ◽  
Vol 287 ◽  
pp. e110-e111
Author(s):  
A.A. Després ◽  
N. Perrot ◽  
L. Tastet ◽  
A. Pouliot ◽  
M. Shen ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Oxidized Phospholipids ◽  
Lipoprotein A ◽  
Pet Ct

Lipoprotein(a) in subjects with familial defective apolipoprotein B100

1992 ◽  
Vol 92 (2-3) ◽  
pp. 203-212 ◽  
Author(s):  
Y.F.Nicholas Perombelon ◽  
John J. Gallagher ◽  
Nicholas B. Myant ◽  
Anne K. Soutar ◽  
Brian L. Knight
Keyword(s):  
Lipoprotein A ◽  
Apolipoprotein B100

scholarly journals Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans

Circulation ◽  
2016 ◽  
Vol 134 (8) ◽  
pp. 611-624 ◽  
Author(s):  
Fleur M. van der Valk ◽  
Siroon Bekkering ◽  
Jeffrey Kroon ◽  
Calvin Yeang ◽  
Jan Van den Bossche ◽  
...  
Keyword(s):  
Arterial Wall ◽  
Oxidized Phospholipids ◽  
Lipoprotein A ◽  
Inflammatory Monocyte

Abstract 235: Prevalence of Lipoprotein(a) Measurements and Extent of Lipoprotein(a) Elevations in 2,266 Patients with Aortic Stenosis: Results from an Academic Echocardiography Laboratory Practice Setting

2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
Michael J Wilkinson ◽  
Gary S Ma ◽  
Calvin Yeang ◽  
Monet Strachan ◽  
Joel Wilson ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Practice Setting ◽  
Oxidized Phospholipids ◽  
Laboratory Practice ◽  
Lipoprotein A ◽  
Causal Risk Factor ◽  
Number Of Patients ◽  
Echocardiography Laboratory ◽  
Ongoing Development ◽  
The University

Background: The LPA gene causes elevated lipoprotein(a) (Lp(a)) levels and causally mediates calcific aortic valve stenosis (AS). Elevated Lp(a) and its associated oxidized phospholipids (OxPL-apoB) predict the progression of pre-existing AS and need for aortic valve replacement and are targets of therapy. Methods: We determined the prevalence and the extent of Lp(a) elevation in patients with AS diagnosed by echocardiography performed at the University of California San Diego between 2010-2015. Severity of AS was classified as critical, severe, moderate, mild, or trace. Lp(a) levels were organized as Lp(a) <30 mg/dL, 30-50 mg/dL, 50-100 mg/dL and >100 mg/dL. Results: 2,266 patients with AS were found, with 130 critical, 333 severe, 477 moderate, 1318 mild, and 8 cases of trace AS. Mean age was 75.0 and range 18-106 years. 51% of patients were male. Prevalence of any Lp(a) measurement was 159/2,266 patients (7.02%). The number (%) of patients with an Lp(a) level was: 1) critical (n=4, 3.1%), 2) severe (n=28, 8.4%), 3) moderate (n=56, 11.7%), 4) mild (n=71, 5.4%), and 5) trace (n=0). The extent of Lp(a) elevation within each AS category is in Table 1: 55/159 (34%), 35/159 (22%) and 19/159 (12%) of patients had Lp(a) >30 mg/dL, >50 mg/dL and >100 mg/dL, respectively. Conclusion: Lp(a) was measured in only 7.0% of patients with AS in an academic setting. Given the ongoing development of therapies to lower Lp(a) in patients with AS, educational efforts are needed to raise awareness of Lp(a) as a causal risk factor for AS.

scholarly journals Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes

2007 ◽  
Vol 27 (8) ◽  
pp. 1788-1795 ◽  
Author(s):  
Stefan Kiechl ◽  
Johann Willeit ◽  
Manuel Mayr ◽  
Brigitte Viehweider ◽  
Martin Oberhollenzer ◽  
...  
Keyword(s):  
Phospholipase A2 ◽  
Cardiovascular Outcomes ◽  
Oxidized Phospholipids ◽  
Lipoprotein A ◽  
Phospholipase A2 Activity
Sign in / Sign up

Export Citation Format

Share Document